StreetAlpha.app
Home › Stocks › SGHT

Sight Sciences, Inc. (SGHT)

Healthcare
$10.49
▼ −0.94%
LAST CLOSE · NOV 17

Sight Sciences sells medical devices for treating glaucoma and dry eye disease, based in Menlo Park, California. It last closed at $10.49 on Nov 17, down 0.94% on the day. The average 12-month price target from 3 analysts is $13.17 (+25.5% from the last close), with a high of $14.00 and a low of $12.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $301K, the largest $301K.

AI Auto Pilots
Is SGHT in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$88.4M
+16.2% vs a year ago
Net income
−$28.4M
−32.1% margin
EPS (diluted)
−$0.52
Free cash flow
−$16.9M
−19.2% margin
Valuation
Market cap
$583.0M
55.6M shares
P/E
–
No P/E while losing money
Price to sales
6.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$77.4M
At Sep 30
Debt
$42.4M
At Sep 30
Shareholder equity
$49.1M
Shares outstanding
55.6M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $49.0M$49.0MFY2021FY2022: $71.3M$71.3MFY2022FY2023: $81.1M$81.1MFY2023FY2024: $79.9M$79.9MFY2024FY2025: $77.4M$77.4MFY2025

From SGHT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on SGHT in the past 90 days
Average 12-month target
$13.17
▲ 25.5% upside

Based on 3 analysts who set a price target on SGHT in the past 90 days. The average target is $13.17, with a high of $14.00 and a low of $12.00, compared with the last close of $10.49.

Low $12.00Avg $13.17High $14.00
Blue marker: last close $10.49
Highest target$14.00
Average target$13.17
Lowest target$12.00
Latest rating changes
UBSTarget raised
Nov 12Buy$8 → $13.50
Piper SandlerReiterated
Nov 5Buy$12
HC Wainwright & Co.Initiated
Oct 15Buy$14
UBSTarget raised
Aug 6Buy$7 → $8
UBSAssumed coverage
Jul 28Buy$7
DateFirmActionRatingPrice target
Nov 12UBSTarget raisedBuy$8 → $13.50
Nov 5Piper SandlerReiteratedBuy$12
Oct 15HC Wainwright & Co.InitiatedBuy$14
Aug 6UBSTarget raisedBuy$7 → $8
Jul 28UBSAssumed coverageBuy$7
Loading…

Technical Analysis

SGHT · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 6% above its 20 day and 14% above its 50 day average. It is 41% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 62), near overbought. The nearest support is the Pivot S1 at $10.33, and the nearest resistance the Pivot R1 at $10.65.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityNormal, 5.2%/day
Key levels
$11.6052 week high+10.6%
$11.60Swing high (Nov 12)+10.6%
$10.65Pivot R1+1.5%
$10.49Pivot+0.0%
$10.49Last close
$10.33Pivot S1−1.5%
$9.8320 day average−6.3%
$9.0650 day average−13.6%
$8.98Swing low (Nov 4)−14.4%
$7.83100 day average−25.4%
$6.23200 day average−40.6%
$3.3852 week low−67.8%
Indicators
RSI (14)62.22Strong, overbought above 70Neutral
MACD0.55Above its signal lineBullish
Stochastic63.6Middle of its rangeNeutral
ADX (14)35.4Trending up
Williams %R-42.3Oversold below −80, overbought above −20Neutral
CCI (20)66.3Oversold below −100, overbought above 100Neutral
Rate of change+11.4%Change over 10 sessionsBullish
ATR (14)$0.55Typical daily range, 5.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for SGHT

What happened before

See how SGHT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow SGHT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How SGHT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in SGHT in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$301K
Largest print
$301K
Loading…

SGHT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲73 buying vs 38 selling
  • ▲Held by funds +1.7 pts
  • ▲Funds holding +19
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding131112+17.0%
In funds' top 1010–
Held by funds41.6%39.9%+1.7 pts
New / increased26 / 4716 / 43+23.7%
Reduced / sold out31 / 730 / 15−15.6%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See SGHT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether SGHT is in one of them and how their past SGHT trades turned out.

SGHT in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered SGHT in an article yet. Here's the latest on the wider market.

About Sight Sciences

Sight Sciences is a medical device company based in Menlo Park, California. It sells surgical devices for treating glaucoma, including the OMNI Surgical System and the SION Surgical Instrument, which surgeons use in procedures to lower eye pressure. The company also sells the TearCare system, a device for treating dry eye disease caused by blocked meibomian glands. Its customers are eye care professionals, mainly ophthalmic surgeons and eye doctors, and the patients they treat.

Headquarters
Menlo Park, CA